In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.

  On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked

  Many people are troubled by stomach problems for many years, so what is the reason? Bad habits and mental stress were once considered to be major factors, but there is another reason that must be mentioned, that is, Helicobacter pylori.   I. Discovery of Helicobacter pylori In 1982, Australian… Continue Reading Do you know about Helicobacter pylori?

  Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer

  Biopharma Dive, a biopharmaceutical website, recently selected the annual pharmaceutical company (Mersha East), the annual biotechnology company (Spark Therapeutics), the annual CEO (Emma Walmsley, GSK), the annual transaction (Takeda $62 billion acquisition of Shire), the annual innovation (RNA Targeted therapy), an annual new drug (Ajin/Nuohua migraine drug Aimovig).  … Continue Reading BioPharma: Six “most” in 2018

  On November 30, Pfizer announced a settlement with AbbVie on a worldwide patent litigation against adalimumab biosimilars. Under the agreement, in the European market, Pfizer’s adalimumab biosimilars will be available for sale upon approval by the EMA. However, in the US market, Pfizer needs to market adalimumab biosimilars on… Continue Reading Pfizer and AbbVie reach a settlement, delaying the launch of Humira-like drugs in the US

  Almost everyone did not notice that the cumulative market value of the three CRISPR listed companies tripled between June 2017 and June 2018, with a cumulative market value of nearly $6 billion. However, in the past six months, the market value of these three companies has fallen by nearly… Continue Reading Progress of the latest clinical trials of 3 CRISPR listed companies

  On November 26, He Jiankui, a scientist at Southern University of Science and Technology, announced that a pair of genetically edited babies named Lulu and Nana were born in China in November. The genes of the twins have been modified to make them naturally resistant to AIDS after birth.… Continue Reading Chinese scientists claim that the world’s first genetic editing baby is born! Naturally resistant to AIDS

  Gump’s troubles In 2013, Gump’s actor, the second American movie star Tom Hanks, who won the Oscar for Best Actor Award for two consecutive years, frankly told the hosts and viewers on a nighttime talk show: “When I went to see a doctor, he said to me, ‘Do you… Continue Reading From lizard venom to a new drug for type 2 diabetes – Lyxumia

  On November 23, the application for the Bayer prostate cancer new drug Xofigo (Rainium Chloride [223Ra] Injection) was officially accepted by CDE. Xofigo was first approved by the FDA on May 15, 2013 for the treatment of advanced bone metastases in castration-resistant prostate cancer. In the Phase 3 ALSYMPCA… Continue Reading Bayer prostate cancer new drug Xofigo applied for listing in China